About Ultimovacs

Company Description

Ultimovacs is a biotech company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.

Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is a limited public liability company listed on the Oslo Stock Exchange in Norway.

Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden. Ultimovacs is an active member of Oslo Cancer Cluster.

Year founded

2011

Served area

Worldwide

Shareholder information

Shares outstanding

34,396,461

IPO

June 3, 2019

Stock exchange(s)

Euronext Oslo

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.